AVE8062: a new combretastatin derivative vascular disrupting agent.
about
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Discovery of new anticancer agents from higher plantsReal-time visualization and quantitation of vascular permeability in vivo: implications for drug deliveryMicrotubule-binding agents: a dynamic field of cancer therapeutics.Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding SiteSynthesis and antiproliferative activities of ottelione a analoguesThe continuing search for antitumor agents from higher plantsNecrosis targeted combinational theragnostic approach using radioiodinated Sennidin A in rodent tumor models.Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancerA perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessmentRole of the cytoskeleton in formation and maintenance of angiogenic sproutsDesign, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4.Synthesis and antitumor molecular mechanism of agents based on amino 2-(3',4',5'-trimethoxybenzoyl)benzo[b]furan: inhibition of tubulin and induction of apoptosis.Cardiovascular toxicity profiles of vascular-disrupting agents.First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agentsBiliary and duodenal drainage for reducing the radiotoxic risk of antineoplastic 131I-hypericin in rat modelsSubstituted oxines inhibit endothelial cell proliferation and angiogenesis.Synthesis and evaluation of diaryl sulfides and diaryl selenide compounds for antitubulin and cytotoxic activity.An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents.Vascular-disrupting agents in oncology.Tubulin-interactive stilbene derivatives as anticancer agents.Tubulin inhibitors: a patent review.Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation.Design and synthesis of aminostilbene-arylpropenones as tubulin polymerization inhibitors.Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.Synthesis, biological evaluation, and structure-activity relationships of tri- and tetrasubstituted olefins related to isocombretastatin A-4 as new tubulin inhibitors.A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis.CuI/1,10-phen/PEG promoted decarboxylation of 2,3-diarylacrylic acids: synthesis of stilbenes under neutral and microwave conditions with an in situ generated recyclable catalyst.Biological Evaluation in Vitro and in Silico of Azetidin-2-one Derivatives as Potential Anticancer Agents.The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors.131I-Evans blue: evaluation of necrosis targeting property and preliminary assessment of the mechanism in animal models.Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
P2860
Q26781365-8AF7EECA-2571-4B8E-854A-8DB8D2A89280Q27006814-E312EC40-960C-45B2-B4F8-79B8F7426871Q27306235-B184C877-5A31-4BCE-9D82-66CD8FA094ABQ27690249-2D5DE394-3722-4E55-9A5F-27062DD27BEFQ28067375-6A5AE0DE-EE5B-4D6B-9F3A-63192396E6B4Q33630497-DFD4E737-A8C8-4068-8D73-13C26804B91CQ33717343-4CFACF72-80CC-4F68-9250-C4F0E19ABF50Q33917524-D1CA1CAC-7F20-4BB2-8033-DB09B10D6D11Q34538659-2805C329-8909-4027-834B-5CDD426FC863Q34765364-5E4C4706-3A36-4D87-815E-85C497401AF2Q34829230-BECBCB93-67A4-4FB0-BBA7-C104078692C6Q35092318-D2F9F78E-817D-4D4A-9E31-6996E93D9E79Q35309200-8FD4548C-A9BE-4740-A33D-F1B9F2192210Q35584746-3D93FCD9-783F-4EF8-8192-692AFB56C5C7Q36132293-DE26A4FE-88EF-4756-9E2C-9F87927B5EB7Q36839418-8F420F6E-A2FC-42F8-ABEA-F42E612917A9Q37071343-6A18690F-6518-47EA-AD0C-037526981F36Q37156368-E8CB25DA-435D-496A-A79E-63AA472DE69DQ37174354-5BEBC7A5-FE3F-43DF-8C1B-07B950895A2CQ37597936-6EB52D91-4E0D-4D94-9293-E0809894DBC3Q37670789-D4B1F6C1-63BA-462D-8A33-6697775CD731Q38073812-C78A42E7-F2E8-4A31-B9B1-A063B4C8D4EBQ38118663-9635851B-5FF4-40FE-A948-AF5D56907FC4Q38169237-146C90EB-14E7-4798-9B2B-A986AAAA2FDDQ38910151-064E5919-68BD-4CC5-860F-117AA04D9CEAQ38963815-C5194B1A-6373-469E-B72E-5AB4F9A1169BQ39010651-C7A5EEAD-CEFB-498D-9213-BD18829B4D64Q39263355-A1AF32EF-753A-46BC-BB7F-D57A3D753239Q42818196-7CB414B6-AE23-4681-B75A-D94969F73040Q43792334-41F8AAAB-DD01-42DD-8EF6-2D21C063E453Q44452260-EA150F0E-767E-4D6E-8F9C-F3AE88C8F466Q44864691-24440767-D338-4FE6-81CD-87A614A3C580Q50218587-A0B701A8-59DA-4A99-8A3B-9D36144F674CQ52627703-2B76998A-9B68-4569-8BF0-216A82D5B1AFQ52674608-2D3ABABA-407E-4430-AF07-E976C0ED1743Q55342361-5AE10BAC-AFEB-4B15-B906-192E0ADBEC82Q55365628-61996E09-4260-4840-AADD-45E2613D4EC3Q57110000-F8D39597-6B6E-4D8C-A4B6-FDC29DD13175
P2860
AVE8062: a new combretastatin derivative vascular disrupting agent.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
AVE8062: a new combretastatin derivative vascular disrupting agent.
@en
AVE8062: a new combretastatin derivative vascular disrupting agent.
@nl
type
label
AVE8062: a new combretastatin derivative vascular disrupting agent.
@en
AVE8062: a new combretastatin derivative vascular disrupting agent.
@nl
prefLabel
AVE8062: a new combretastatin derivative vascular disrupting agent.
@en
AVE8062: a new combretastatin derivative vascular disrupting agent.
@nl
P2860
P1476
AVE8062: a new combretastatin derivative vascular disrupting agent
@en
P2093
Cristiana Sessa
P2860
P304
P356
10.1517/13543780903213697
P407
P577
2009-10-01T00:00:00Z